NCT07033455CompletedEarly phase 1
A Trial of HRS-1893 in Healthy Volunteers
A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of HRS-1893 in Healthy Participants
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
The purpose of this study is to assess the safety and PK characteristics of a single oral dose of HRS-1893 in healthy voluunters.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 20 May 2025
- Start date
- 25 Jun 2025
- Primary completion date
- 5 Sept 2025
- Lead sponsor
- Atridia Pty Ltd.
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT07033455
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 20
- From 25 Jun 2025 to the primary completion date, 5 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History or evidence of clinically significant disorders
- History of cardiomyopathy and/or unexplained heart failure
- Individuals with a history of drug allergies, specific allergies
Lab values
- Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.
Who the study is looking for
- Healthy white participants;
- Ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written informed consent, be able to comply with all the requirements, and able to complete the study.
- Male aged between 18 to 55 years of age (inclusive)
- Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, body mass index (BMI) between 19.0 and 30.0 kg/m2 (inclusive) at screening.
- Negative pregnancy test for women of childbearing potential (WOCBP) at baseline. Men and WOCBP must agree to take highly effective contraceptive methods
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Linear Clinical Research Coordinator of this site? Confirm its status | Nedlands | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.